What are Migraitan tablets used for?
Do you need fast acting migraine relief? Use Migraitan tablets. In addition the tablets treat symptoms such as nausea and sensitivity to light and sound.
Gets to work in as little as 30 minutes.
What is a migraine?
Migraine is characterized by a throbbing pain on one side of the head. Also, nausea, vomiting and increased sensitivity to light may occur. It is a common condition. 1 in 5 women suffer from migraine. As do 1 in 15 men. There are several types of migraine, for instance.
Migraine with aura, Warning signs such as flashing lights can indicate a migraine is coming on. Secondly you can have a migraine without flashing lights. Finally you can experience flashing lights without the headache.
Adults (18-65 years of age)
The recommended dose is a single 50 mg tablet that should be swallowed whole with water. It is advisable that Sumibril/Migraitan be taken as soon as possible after the onset of a migraine headache although it is effective at whatever stage of the headache it is taken.
If there is a response to the first tablet but the symptoms recur, a second tablet may be taken. However, this must be at least 2 hours after the first tablet. No more than two 50 mg tablets (total dose 100mg) may be taken in any 24 hour period or to treat the same attack.
See our pain relief range
Immune System Disorders
Hypersensitivity reactions ranging from cutaneous hypersensitivity to anaphylaxis.
Nervous System Disorders
Dizziness, drowsiness, sensory disturbance including paraesthesia and hypoaesthesia.
Seizures, although some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures there are also reports in patients where no such predisposing factors are apparent; Tremor, dystonia, nystagmus, scotoma.
Flickering, diplopia, reduced vision. Loss of vision (usually transient). However, visual disorders may also occur during a migraine attack itself.
Bradycardia, tachycardia, palpitations, cardiac arrhythmias, transient ischaemic ECG changes, coronary artery vasospasm, angina, myocardial infarction (see section 4.3 and 4.4).
Transient increases in blood pressure arising soon after treatment. Flushing.
Hypotension, Raynaud’s phenomenon.
Respiratory, Thoracic and Mediastinal Disorders
Nausea and vomiting occurred in some patients but the relationship to sumatriptan is not clear.
Musculoskeletal,and Connective Tissue Disorders
The following symptom is usually transient and may be intense and can affect any part of the body including the chest and throat:
Sensations of heaviness
General Disorders and Administration Site Conditions
The following symptoms are usually transient and may be intense and can affect any part of the body including the chest and throat:
Pain, sensations of heat or cold, pressure or tightness
The following symptoms are mostly mild to moderate in intensity and transient:
Feelings of weakness, fatigue.
Minor disturbances in liver function tests have occasionally been observed.
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms and Signs
In the event of an overdose, medical advice should be sought immediately.
There have been some reports of over dosage with Sumatriptan. Doses in excess of 400 mg orally were not associated with side effects other than those mentioned in Section 4.8
If over dosage occurs, the patient should be monitored for at least 10 hours and standard supportive treatment applied as required.
It is unknown what effect haemodialysis or peritoneal dialysis has on the plasma concentrations of Sumatriptan.